SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

NRx Pharmaceuticals, Inc. (NRXP) Q3 Revenue Rose to $1.2M; Net Loss Narrowed to $2.2M

Q3 2026 net patient service revenue was $1.2M, versus $0.2M a year earlier; net loss was $2.2M, or $0.05 per share, versus $5.9M, or $0.27 per share. The company said FDA-approved preservative-free ketamine is commercially launching.Material DetailsContext by AI AnalystThis is an early commercial-s…

NRXP

Related stories